Alpha 2.0
Login Register
» Authors » Qisu Zhang

Qisu Zhang

Explore the profile of Qisu Zhang including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 19
Citations 165
Followers 0
Related Specialties
Pharmacology
General Medicine
Health Services
Top 10 Co-Authors
Allison Keshishian
Oluwaseyi Dina
Jeffrey Trocio
Lisa Rosenblatt
Vineet Chopra
Alpesh Amin
Jack Mardekian
Lien Vo
Xianchen Liu
Hannah Le
Published In
J Manag Care Spec Pharm
Curr Med Res Opin
BMJ Qual Saf
Adv Ther
Gen Hosp Psychiatry
Affiliations
Soon will be listed here.
Recent Articles
11.
Improving peripherally inserted central catheter appropriateness and reducing device-related complications: a quasiexperimental study in 52 Michigan hospitals
Chopra V, OMalley M, Horowitz J, Zhang Q, McLaughlin E, Saint S, et al.
BMJ Qual Saf . 2021 Mar; 31(1):23-30. PMID: 33782091
Background: The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC) provides evidence-based criteria for peripherally inserted central catheter (PICC) use. Whether implementing MAGIC improves PICC appropriateness and reduces complications is unknown....
12.
The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies
Rubin D, Griffith J, Zhang Q, Hepp Z, Keshishian A
Inflamm Bowel Dis . 2020 Oct; 27(8):1201-1209. PMID: 33107564
Background: Although there is evidence that anti-tumor necrosis factor (TNF) utilization earlier in the inflammatory bowel disease (IBD) course and before the onset of disease-related complications leads to improved patient...
13.
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, et al.
J Manag Care Spec Pharm . 2020 Apr; 26(5):639-651. PMID: 32347184
Objective: To compare hospitalization risks (all-cause, stroke/SE-related, and MB-related) and associated health care costs among elderly nonvalvular AF (NVAF) patients in the Medicare population who initiated warfarin, dabigatran, rivaroxaban, or...
14.
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population
Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, et al.
BMC Cardiovasc Disord . 2019 Jun; 19(1):142. PMID: 31195999
Background: Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among patients with non-valvular atrial fibrillation...
15.
Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics
Shah A, Xie L, Kariburyo F, Zhang Q, Gore M
Adv Ther . 2018 Oct; 35(11):1994-2014. PMID: 30269292
Introduction: Long-acting injectable (LAI) antipsychotic use may reduce healthcare resource utilization compared with oral antipsychotic use by improving adherence and reducing dosing frequency. Our goal was to examine treatment patterns,...
16.
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population
Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, et al.
J Manag Care Spec Pharm . 2018 Sep; 24(11):1116-1127. PMID: 30212268
Background: The ARISTOTLE trial demonstrated that apixaban had significantly lower rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct clinical trials between apixaban and other direct...
17.
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, et al.
J Manag Care Spec Pharm . 2018 Aug; 24(9):911-920. PMID: 30156450
Background: Clinical trials have shown that direct oral anticoagulants (DOACs)-including dabigatran, rivaroxaban, apixaban, and edoxaban-are at least as effective and safe as warfarin for the risk of stroke/systemic embolism (SE)...
18.
Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan
Amin A, Keshishian A, Vo L, Zhang Q, Dina O, Patel C, et al.
J Med Econ . 2017 Oct; 21(3):244-253. PMID: 29047304
Aims: To compare the risk of all-cause hospitalization and hospitalizations due to stroke/systemic embolism (SE) and major bleeding, as well as associated healthcare costs for non-valvular atrial fibrillation (NVAF) patients...
19.
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, et al.
Curr Med Res Opin . 2017 Jun; 33(9):1595-1604. PMID: 28635338
Objective: To compare the risk and cost of stroke/systemic embolism (SE) and major bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular atrial fibrillation (NVAF) patients. Methods: Patients...